Search

Displaying results 4451 - 4460 of 8517 in total
  1. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    The use of the plant species _Cannabis sativa_ and _Cannabis indica_, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a … isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011].

  2. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.

  3. Drug

    Meningococcal polysaccharide vaccine group A

    go.drugbank.com/drugs/DB13889
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

  4. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.

  5. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

  6. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning

  7. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.

  8. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

  9. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as … In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality.

  10. Drug

    Fluprednidene acetate

    go.drugbank.com/drugs/DB14634
    Investigational

    It has anti-inflammatory and anti-allergic properties.